Member Info for comeonvog

Engr. Yusuf K. N'jie, Managing Director, Optimum Petroleum Development Company, commented, "We are pleased to continue to support LEKOIL by deferring their obligations which were due this quarter. We remain confident in LEKOIL's ability to by July this year, raise the financing that is required for the commencement of the appraisal drilling programme for OPL 310 which we truly believe is a world class strategic asset."

TaffEvans if i remember right you were pumping BAGR , seem to remember that went well.

Reminds me of WSG when they bought the ferry. FFS just get the deeps flowing, o ye i forgot don't give a flying F about the PI'''''''''''''''''''s. And why only a three month lock in if it's such a great deal.

GIT , was not my intention to deramp here as i respect this board. My comments are towards MM and as Kala just pointed out "Not a game changer - it's the same old same old - show us the tonnage".
For me to be pleased i would like an update every month with production figures , it's not lot to ask after all this time. Lets face it , the people on the ground will know the instant they really start to build so why can't we be kept in the loop.IMO

GETINTHERE Does it really matter how many i own, i can comment on any stock no matter my holding. I think that interview was poor and to mention " the goldyilocks phase twice , well I want to know about production nothing more nothing less, he has had my cash for a long time and i want to see a return.

Got to admit it didn't inspire me to buy more. Hardly talked about the project just about commodity prices and we all know them. Could do with monthly report on production/ targets to get some interest if we really are going to see a substantial ramp up, why not keep us informed. IMO
Volume is pitiful and from that interview i can fully understand. One good point no big sell off today.

ocelot Good shout on the FCF . Plenty to look forward to this year with an extra 10% bpd from Sarta could take us close to 40K

Read this Lazygun.....They only need $10 million by February 2020 -

a payment estimated at c. US$10 million. LEKOIL is also required to show its ability by February 2020 to raise 42.86 per cent. of the drilling costs for one appraisal well, which is estimated to be c.US$28 million.

Ability is the key word.

You called this correct , but where from here. Must be buying territory soon , or is the drop never going to end.

BOD brain dead i concur.

Risk V reward. I'm not here for 20% i am looking for 300/400%. If the yanks like us we go up big time. IMO
FDA Q1 this year s now in my calendar.

Jarv55 Could well do after the FDA meeting in Q1 this year. What i like is a lot of the work done here has been paid for when the SP was over £2/£3. We get to buy at 40p.

you seen the news on MPH , we were right. Sorry for O.t.

I now wonder if this company will now start to attract some positive press. Plenty will now be looking to give this some value. IMO

I stated when we got the 2b Asteroid RNS nov 2019 that it was good news. This is confirmation all is still on track. I really hope they have success with this as it's geared towards children.Well done MPH

As part of the PRIME pathway, Mereo has discussed the results of the Phase 2b ASTEROID study with the EMA. On the basis of the Phase 2b data, the EMA supports the initiation of the planned pivotal pediatric study in Europe on the basis of the previously approved pediatric investigational plan (PIP). This is based on a primary endpoint of fracture rate over a 12-month period in approximately 165 children aged 5 to <18 years old.

Plenty going on at MPH

Mereo's broader pipeline consists of four additional clinical-stage product candidates; acumapimod for the treatment of acute exacerbations of chronic obstructive pulmonary disease ("AECOPD"), leflutrozole for the treatment of hypogonadotropic hypogonadism ("HH") in obese men, navicixizumab for the treatment of platinum-resistant ovarian cancer (recently licensed to Oncologie), and etigilimab for patients with advanced or metastatic solid tumors.

If the yanks like it we get the funding, not long to wait.

Mereo expects to conduct a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in Q1 2020 to discuss the data from the Phase 2b ASTEROID study as well as the proposed pediatric pivotal study design. Mereo intends to announce the outcome of these discussions following the meeting.

There are no currently approved therapies for osteogenesis imperfecta, and treatment options are greatly needed."

This is big news , "We believe these additional endpoint data, together with the totality of the 12-month topline data and trend in fracture rate reduction in the high dose cohort, are fully supportive of moving forward with our planned pivotal trial in children with OI. To this end, we have made additional progress on the regulatory front, including a positive recent meeting with the European Medicines Agency ("EMA"), and are currently preparing for a Type B End-of-Phase 2 meeting with the FDA, scheduled for the first quarter of 2020."

mrcautiousut does that not make him the ideal candidate for the job, to peddle all the disinformation and spiel on every RNS. A5 801, A6, A8, moved pipes here drill there, mud stuck , drill stuck, side track ect ect. frigin boring